Markets
markets

West Pharmaceutical jumps on continued GLP-1 demand

West Pharmaceutical, which manufactures injectable pharmaceutical packaging, rose more than 14% in early trading after it reported earnings results that beat Wall Street estimates, bolstered by sales of components that go into GLP-1 pens.

The company reported adjusted earnings per share of $1.96 for the quarter, more than the $1.68 analysts polled by FactSet were penciling in. West also reported sales of $805 million, crushing the $785.7 million the Street was expecting.

The company attributed the strong report to growth in its GLP-1 elastomers, which are small rubber components that go into the pens that deliver the blockbuster weight-loss drugs made by Novo Nordisk and Eli Lilly. Those parts accounted for 9% of sales for the quarter, the company said.

More Markets

See all Markets
markets

SpaceX gets a wave of bullish ratings from Wall Street analysts

SpaceX received more than a dozen positive analyst calls on Tuesday — including from major Wall Street banks — as they initiate coverage on Elon Musk’s space and AI company.

SpaceX went public on June 12 at a $2.2 trillion valuation, the largest debut in history. While the company hasn’t yet posted a profit, it seems to have convinced Wall Street that it will get there and grow its valuation on the way.

Of the at least 17 analysts that gave a rating on Tuesday, all but one gave it a “buy” or “outperform” rating. MoffettNathanson was "neutral."

The ratings come as SpaceX joined the Nasdaq 100 index, a benchmark tech-heavy basket of companies that underpins millions of portfolios. The inclusion adds built-in demand for the stock from index funds and ETFs.

Still, SpaceX fell more than 5% on Tuesday amid a broader sell-off, and is currently effectively flat from its opening price of $150 a share.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.